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Abstract
BACKGROUND
BACKGROUND: The death rate for prostate cancer (PrCA), the most commonly diagnosed cancer in
African-American (AA) men, is twice the rate of European-American (EA) men. AA men in South Carolina
have the highest age-adjusted death rate in the nation. Studies have shown that treatment offered to AA
men with PrCA is systematically different from that offered to EA men. METHODS
METHODS: Surveys were mailed
to 1,866 men in South Carolina with a diagnosis of PrCA. South Carolina men diagnosed with PrCA
between 1996 and 2002 were eligible to participate. We performed a descriptive assessment of the
factors that influenced PrCA treatment decisions. RESULTS
RESULTS: The treatment choices of AA men were
significantly more likely to be influenced by pain and significantly less likely to be influenced by potential
for cure compared to EA men. CONCLUSIONS
CONCLUSIONS: Providers must be cognizant of the factors that influence
treatment, particularly in AA men. Despite the national undertaking to eliminate health disparities, the
United States is far from implementing a comprehensive focus on the health of AA men, despite their
elevated PrCA morbidity and mortality rates.
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Abstract
BACKGROUND: The death rate for prostate cancer (PrCA), the most commonly diagnosed cancer in African-American (AA) men, is twice the rate of
European-American (EA) men. AA men in South Carolina have the highest
age-adjusted death rate in the nation. Studies have shown that treatment
offered to AA men with PrCA is systematically different from that offered to
EA men. METHODS: Surveys were mailed to 1,866 men in South Carolina with
a diagnosis of PrCA. South Carolina men diagnosed with PrCA between 1996
and 2002 were eligible to participate. We performed a descriptive assessment of the factors that influenced PrCA treatment decisions. RESULTS: The
treatment choices of AA men were significantly more likely to be influenced
by pain and significantly less likely to be influenced by potential for cure
compared to EA men. CONCLUSIONS: Providers must be cognizant of the
factors that influence treatment, particularly in AA men. Despite the national
undertaking to eliminate health disparities, the United States is far from
implementing a comprehensive focus on the health of AA men, despite their
elevated PrCA morbidity and mortality rates.
Key Words: tumor grade, tumor stage, diagnosis, pain, cure, impotence,
incontinence, fatalism, avoidance, morbidity

Introduction
Studies have shown that treatment offered to African-American (AA) men
with prostate cancer (PrCA) is systematically different from that offered to
European-American (EA) men. At a comparable disease stage, AA men were
less likely to receive aggressive treatment fpr PrCA compared to EA men.1-5
More recent studies have found that AA men with PrCA are more likely than
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EA men to receive conservative management or watchful waiting, after
adjusting for stage, age, life expectancy, and co-morbidity. They are also more
likely than EA men to receive no treatment for PrCA.1,4,6
There are a variety of treatment options for patients with the same set
of clinical factors; therefore, the implemented treatment must be influenced
by non-clinical factors. These other factors may contribute to the differences
in observed treatments received by AA vs. EA PrCA patients. The aim of
this study is to describe and compare racial differences in social and clinical
factors that may influence PrCA treatment decisions. In order to assess racial
differences in factors that influence treatment decisions we utilized data from
South Carolina, a state in which AA men have among the highest incidence
and mortality rates in the country and world.7-9,10

Methods and Materials
PrCA cases from an eight-county area in the Midlands (area around
Columbia) South Carolina were identified through the South Carolina Central
Cancer Registry (SCCCR). All men diagnosed between 1996 and 2002 were
eligible to participate. Due to the time lapse between 2002 and 2006, many
men were deceased or had health conditions that prevented physicians from
providing consent for the patient to be contacted. A total of 1,866 patients
were able to participate in the study. A total of 541 responses were received,
yielding a 29% response rate.
The variables under investigation were framed by Holmboe et al.,11
who developed a taxonomy that organized aspects of treatment into
four Axes: External Information, Intrinsic Characteristics of Treatment,
Personal Impressions, and Economic Concerns. This taxonomy provides the
groundwork for understanding patients’ preferences and how they connect
to all aspects of decision-making and treatment satisfaction. The variables
collected from this survey include: age when first screened for PrCA, number
of doctor visits, initial treatment and date, subsequent treatments and
dates, person who most influenced treatment decision, clinical factors that
influenced treatment decision, PSA level change, type of insurance, number
of people in household, and accessibility to doctor visits.
Descriptive analyses were performed using SAS (version 9.1).
Responders were compared to non-responders in order to determine the
representativeness of the study sample. Frequency distributions by race
were used to evaluate the treatment and diagnostic variables across racial
groups. Bivariate analyses were conducted using the t-test or chi-square
test, as appropriate, to assess the associations between race/ethnicity and all
variables, and differences between racial groups.
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Results
Comparison of responders to non-responders revealed significant
differences (p<.0001) in both race and marital status between the groups, with
the non-responder sample being approximately 48% EA (as opposed to 80%
in the responder sample) and 75% of the men in this group (vs. 86% of the
responders) being married. Other characteristics of the non-responder sample
were similar to those of responders, (e.g., having a mean ages of 66 and 71
years, 81% of the men in both groups had localized disease, and 76% of nonresponders had moderately well-differentiated disease (vs. 71% of responders).
Table I. shows the percentages for the variables used in this analysis by race/
ethnicity. The sample was 80% EA and 20% AA. Over 78% of the men were
65 years and older and 85.8% were married. The majority of the sample had
localized (81%) and moderately well-differentiated (72%) disease. AA men
were more likely to be screened at an earlier age (58 vs 61.3 years), single, and
living alone compared to EA men. PSA changes were significantly less likely
to occur since last treatment in AA men (55%) than in their EA counterparts
(66%).
Some clinical factors differed significantly between the groups; however,
no social factors were significant. AA men were significantly (p<.05) less
likely to report cure and significantly more likely to report pain as reason for
treatment compared to EA men (Table II). The most commonly reported social
influence was the doctor. However, this reason did not vary significantly by
race.

Discussion
We observed evidence of differences in clinical factors by race that may
influence PrCA treatment decisions. Compared to EA men, AA men were less
likely to report that cure and more likely to report that pain influenced their
treatment decision. Several plausible reasons could explain the differences
between AA and EA men on factors associated with treatment decisions.
Cancer fatalism, the belief that death is inevitable when cancer is present, has
been identified as a barrier to participation in cancer screening, detection,
and treatment.12 Race also is associated with cancer fatalism.12-17 Powe found
elderly African Americans had higher mean fatalism scores compared to
elderly EAs.17 Fatalism and the belief that treating cancer was useless emerged
as a major theme in a qualitative study of AAs by Greiner et al.18 Another
reasonable explanation for lower percentages of AA men reporting cure as
a reason for treatment might be their belief that God is the only one able
to heal or cure cancer. The dependency on God to heal has been reported
in several studies.19-22 Investigators at Emory University School of Medicine
found some AAs believed that prayer and faith in God was the only cure for
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Table 1. Participant Characteristics

Characteristics
Age (mean)** t-test
Marital Status*
Unmarried (sep, divorce,
widow)
Married
Unknown
Treatment Type
Watchful Waiting
Surgery
Radiation
Hormone Therapy
Other (chemo, other)
Unknown* (including missing)
Treatment Aggressiveness†
Aggressive
Conservative
Unknown (missing)
Tumor grade
Well differentiated
Moderately differentiated
Poorly differentiated
Undifferentiated
Not determined
Tumor stage
Localized
Regional
Distant Metastasized
Unstaged
Lives with wife or partner*
Yes
No
Missing
Number of other people in the
household*
0
1
>1
Missing
Difficulty attending doctor
visits*
Yes
No
Missing

African
American
(n = 110)
N (%)

European
American
(n = 431)
N (%)

68 (sd-8)

72 (sd-8)

24 (22)

35 (8)

83 (75)
3 (3)

381 (88)
15 (3)

6 (5)
58 (53)
43 (39)
10 (9)
3 (3)
2 (2)

20 (5)
224 (52)
176 (41)
59 (14)
7 (2)
0 (0)

90 (86)
15 (14)
5 (5)

350 (82)
79 (18)
2 (.5)

5 (5)
80 (73)
17 (15)
1 (1)
7 (6)

37 (9)
307 (71)
65 (15)
1 (.2)
21 (5)

88 (80)
17 (15)
1 (1)
4 (4)

348 (81)
61 (14)
2 (.5)
20 (5)

84 (79)
23 (22)
3 (3)

379 (89)
45 (11)
7 (2)

18 (16)
62 (56)
24 (22)
6 (5)

49 (11)
327 (76)
45 (10)
10 (2)

Χ2 (p-value)
-4.30 (<.0001)
16.94 (.0002)

.13 (.7216)
.02 (.8875)
.11 (.7394)
1.67 (.1969)
.59 (.4433)
7.87 (.0050)
.9916 (.3193)

3.34 (.5025)

1.63 (.8035)

9.06 (.0026)

18.21 (.0004)

12.10 (.0005)
8 (7)
101 (93)
1 (1)

6 (1)
423 (99)
2 (.5)

* - Significant chi-square (p-value .05) † - Aggressive treatment includes surgery,
chemotherapy, and radiation treatment; conservative treatment includes hormone therapy
and watchful waiting.
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Table II. Social and Clinical Influences of Treatment

Influences
Social ‡
Doctor
Family
Friend
Yourself
Other
Clinical
Cure*
Impotence
Incontinence
Pain*
Other
None*

African
American
(n = 110)
N (%)

European
American
(n = 432)
N (%)

Χ2 (p-value)

60 (55)
27 (25)
4 (4)
36 (33)
1 (1)

248 (57)
93 (22)
10 (2)
163 (38)
6 (1)

.29 (.5885)
.46 (.4962)
.61 (.4353)
.94 (.3310)
.16 (.6907)

72 (65)
30 (27)
25 (23)
13 (12)
4 (4)
14 (13)

362 (84)
96 (22)
88 (20)
15 (3)
39 (9)
18 (4)

18.98 (<.0001)
1.23 (.2682)
.30 (.5948)
12.41 (.0004)
3.51 (.0610)
11.51 (.0007)

* - Significant chi-square (p-value .05)
‡ - Some observations had multiple social influence choices.

cancer.19 Lastly, because PrCA tends to spread to bone, bone pain is a major
source of morbidity in patients with advanced disease. A study of older (> 60
years) cancer survivors found pain was the most reported symptom of cancer
treatment and being AA was associated with more cancer symptoms. Because
of this, pain avoidance may be a higher priority for AA men.23
There are some study limitations. Though high in comparison to mail
surveys, our response rate was only about one-third. The accuracy of the
reporting on treatment influences may have been compromised by recall-bias
that, in turn, might be influenced by the presence of symptoms, including
those resulting from treatment. However, we were most interested in the
main social and clinical influences associated with treatment, and these are
most likely to be remembered after a diagnosis and treatment of a major
disease. Additional research is needed to understand the relative importance
of factors influencing the treatment decisions and their impact on the health
status and life span of AA men.
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